Aerami Therapeutics

Veja o organograma con seus 10 executivos principais

Biografias mais buscadas da Aerami Therapeutics

• Joshua Ziel, Chief Operating Officer and Interim Chief Executive O...
• Anne Whitaker, Chairman of the Board
• Adam Stern, Director

Criar um alerta
para seguir os movimentos de executivos da Aerami Therapeutics.

Aerami Therapeutics possui 2.277 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Histogen has filed for bankruptcy protection  (publicado em 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado em 18 de abril de 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado em 16 de abril de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Vik Bajaj - Director da Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de Aerami Therapeutics

• Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
• Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress
• Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension
• Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension
• Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference
• Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
• Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
• Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress
• Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week
• Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer
• View more press releases Close

Redes sociais sobre Aerami Therapeutics

• Aerami Therapeutics na Wikipedia, Google News e Yahoo Finance
• Aerami Therapeutics na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Joshua Ziel

Ligue para a Aerami Therapeutics em +1 415...

Veja o organograma

Register to receive your alert

Relatório um erro